TABLE 3.
KEGG enrichment analysis of targets.
| Description | GeneRatio | BgRatio | p-value | p-adjust | Q-value |
|---|---|---|---|---|---|
| Fcepsilon RI signaling pathway | 11/41 | 68/8108 | 1.61E-14 | 2.08E-12 | 5.82E-13 |
| Prolactin signaling pathway | 11/41 | 70/8108 | 2.26E-14 | 2.08E-12 | 5.82E-13 |
| Lipid and atherosclerosis | 14/41 | 215/8108 | 1.04E-12 | 6.13E-11 | 1.72E-11 |
| AGE-RAGE signaling pathway in diabetic complications | 11/41 | 100/8108 | 1.33E-12 | 6.13E-11 | 1.72E-11 |
| PI3K-Akt signalling pathway | 12/41 | 139/8108 | 2.06E-12 | 7.59E-11 | 2.13E-11 |
| TNF signaling pathway | 11/41 | 112/8108 | 4.74E-12 | 1.45E-10 | 4.07E-11 |
| Kaposi sarcoma-associated herpesvirus infection | 13/41 | 194/8108 | 5.52E-12 | 1.45E-10 | 4.07E-11 |
| ErbB signaling pathway | 10/41 | 85/8108 | 8.02E-12 | 1.71E-10 | 4.79E-11 |
| Colorectal cancer | 10/41 | 86/8108 | 9.04E-12 | 1.71E-10 | 4.79E-11 |
| Growth hormone synthesis, secretion and action | 11/41 | 119/8108 | 9.30E-12 | 1.71E-10 | 4.79E-11 |
| Relaxin signaling pathway | 11/41 | 129/8108 | 2.27E-11 | 3.79E-10 | 1.06E-10 |
| Prostate cancer | 10/41 | 97/8108 | 3.09E-11 | 4.74E-10 | 1.33E-10 |
| Endocrine resistance | 10/41 | 98/8108 | 3.43E-11 | 4.85E-10 | 1.36E-10 |
| Coronavirus disease - COVID-19 | 13/41 | 232/8108 | 5.34E-11 | 7.02E-10 | 1.97E-10 |
| C-type lectin receptor signaling pathway | 10/41 | 104/8108 | 6.26E-11 | 7.20E-10 | 2.02E-10 |
| T cell receptor signaling pathway | 10/41 | 104/8108 | 6.26E-11 | 7.20E-10 | 2.02E-10 |
| Insulin resistance | 10/41 | 108/8108 | 9.16E-11 | 9.67E-10 | 2.71E-10 |
| Pancreatic cancer | 9/41 | 76/8108 | 9.46E-11 | 9.67E-10 | 2.71E-10 |
| EGFR tyrosine kinase inhibitor resistance | 9/41 | 79/8108 | 1.35E-10 | 1.31E-09 | 3.67E-10 |
| Non-alcoholic fatty liver disease | 11/41 | 155/8108 | 1.68E-10 | 1.55E-09 | 4.34E-10 |